ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Parasite and Host
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1599766
Evaluation of Beauvericin's Activity and Mode of Action Against All Life Stages of L. tropica for Cutaneous Leishmaniasis Therapy
Provisionally accepted
Lynn Al Samra
Mohamad El NahasIlham MneimnehAia SinnoSima Tokajian
Kelven Rahy
Sergio Thoumi
Lazo AliWael Yammine
Charbel Al Khoury*- Lebanese American University, Beirut, Lebanon
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Leishmaniasis, particularly its cutaneous form caused by Leishmania tropica, remains a significant global health concern due to the limitations of current treatments, including drug resistance, toxicity, and inconsistent efficacy. This study investigates the potential of Beauvericin (BEA), a fungal secondary metabolite, as an alternative antileishmanial agent.Objectives: This study investigates the potential of Beauvericin (BEA), a fungal secondary metabolite, as an alternative antileishmanial agent.We assessed the efficacy of BEA against different developmental stages of L. tropica using in vitro assays and an in vivo Galleria mellonella infection model. The ability of L. tropica to develop resistance to BEA and its effects on the parasite's gene expression profile were also examined.Results: BEA exhibited potent antileishmanial activity with equipotency across both promastigote and amastigote stages of L. tropica, with IC50 values of 0.25 µM and 0.27 µM, respectively, significantly lower than those of miltefosine. Mechanistically, BEA acts as a calcium ionophore, inducing a marked increase in intracellular calcium levels, which serves as the primary cytotoxic event. Transcriptomic profiling further revealed that BEA-induced calcium dysregulation triggers secondary cellular responses involving calcium homeostasis, lipid metabolism, and stress response, contributing to its multifaceted mechanism of action. The G. mellonella model demonstrated that BEA significantly reduced parasite burden, improved survival rates. Notably, BEA showed a slower rate of resistance development compared to ML, indicating its potential as a more sustainable treatment option.Conclusions: BEA is a promising candidate for antileishmanial therapy, demonstrating superior efficacy, a broad mechanism of action, and a favorable resistance profile compared to ML.Further investigations in mammalian models are warranted to validate BEA's potential as a novel, cost-effective treatment for leishmaniasis.
Keywords: Leishmaniasis, Leishmania tropica, Beauvericin, Drug Resistance, RNA-Seq, Galleria mellonella model
Received: 25 Mar 2025; Accepted: 16 May 2025.
Copyright: © 2025 Al Samra, El Nahas, Mneimneh, Sinno, Tokajian, Rahy, Thoumi, Ali, Yammine and Al Khoury. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Charbel Al Khoury, Lebanese American University, Beirut, Lebanon
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.